CORONA Remedies to deduct TDS on dividend; deadline June 19, 2026
CORONA Remedies recommended a final dividend of ₹10 per share. Shareholders must update details by June 19, 2026, for TDS compliance. Tax rates vary based on residency and documentation. Dividend payment is subject to AGM approval.
This is a routine compliance announcement related to tax regulations on dividend payouts. It does not introduce new business strategies, financial results, or significant corporate actions that would materially impact the company's operations or stock price.
The announcement is a procedural update regarding tax deductions on dividends, which is a standard requirement. While it details the dividend recommendation, the primary focus is on tax compliance and documentation, which does not inherently indicate a positive or negative financial outcome.
CORONA Remedies Limited has issued a communication to its shareholders regarding the Tax Deduction at Source (TDS) applicable on dividends. The Board of Directors, in a meeting held on May 11, 2026, recommended a final dividend of ₹10 per equity share for the Financial Year 2025-26. This recommendation is subject to shareholder approval at the upcoming 22nd Annual General Meeting (AGM).
The dividend will be paid to shareholders of record as of Friday, June 19, 2026. Shareholders are advised to ensure their bank details, PAN, and KYC are updated with their Depository Participants for timely credit of dividends. The company is required to withhold taxes on dividends paid from April 01, 2026, as per the Income Tax Act, 2025. The withholding tax rate varies based on the shareholder's residential status and submitted documentation.
Shareholders are requested to update their details and submit necessary tax exemption documents or declarations by Friday, June 19, 2026. This includes specific forms like Form 121 for resident individuals and relevant declarations for other categories, including non-residents. Failure to provide complete and accurate documentation by the deadline may result in higher TDS rates being applied. The company has provided links to various forms and annexures on its website for shareholder convenience.
What to do with a filing like this
CORONA Remedies Limited filed this with the NSE as a statutory disclosure, categorised under dividend. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by CORONA Remedies Limited. Read the original for the full detail.